Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price & Analysis
Crinetics Pharmaceuticals, Inc. (CRNX) rose 4.45% to USD 34.97 as of June 10, 2026 at 00:57 UTC, according to Nexqual real-time market data.
CRNX last closed at USD 33.48; the session ranged USD 33.54–35.07 on volume of 884,522 shares. Market capitalization is $3.69B, with a 52-week range of USD 25.83–57.99 (NMS). Source: Nexqual, June 10, 2026 at 00:57 UTC.
Key Statistics (as of June 10, 2026 at 00:57 UTC)
| Price | USD 34.97 |
|---|---|
| Change | ▲ 4.45% (up) |
| Previous Close | USD 33.48 |
| Open | USD 33.77 |
| Day Range | USD 33.54 – 35.07 |
| 52-Week Range | USD 25.83 – 57.99 |
| Volume | 884,522 shares |
| Market Cap | $3.69B |
| Exchange | NMS |
Technical Analysis (CRNX)
Nexqual's technical model rates CRNX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.22 (neutral) |
| vs SMA50 | Below (USD 37.55) |
| MACD | -1.2 (negative) |
Analyst Ratings (CRNX)
Wall Street analysts rate CRNX "None" based on 14 analysts, with a mean price target of USD 83.14 (range USD 55–97), per Nexqual as of June 10, 2026 at 00:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 83.14 |
| High Target | USD 97 |
| Low Target | USD 55 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (CRNX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.23 |
| Revenue Estimate | $14.85M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.23 vs est -1.2 ▼ miss |
| 2025-12-31 | USD -1.29 vs est -1.37 ▲ beat |
| 2025-09-30 | USD -1.38 vs est -1.25 ▼ miss |
| 2025-06-30 | USD -1.23 vs est -1.1 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Financials & Fundamentals (CRNX)
| Total Revenue | $18.07M |
|---|---|
| Revenue Growth (YoY) | +2873.40% |
| Gross Margin | +0.00% |
| Operating Margin | -1307.79% |
| Profit Margin | +0.00% |
| ROE | -39.17% |
| Debt / Equity | 3.74 |
| Current Ratio | 18.6 |
| Total Cash | $1.29B |
| Total Debt | $47.85M |
| Free Cash Flow | $-242.14M |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Financial Health Score (CRNX)
Nexqual rates Crinetics Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:57 UTC.
| Growth | Strong — Revenue +641% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.29B cash vs $48M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$242M, burning cash |
| Efficiency | Critical — ROE -39%, ROA -24.7% |
Ownership (CRNX)
| Insider Ownership | +1.59% |
|---|---|
| Institutional Ownership | +120.15% |
| Shares Outstanding | 105.44M |
| Float | 95.58M |
| Short % of Float | +14.04% |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
Leadership (CRNX)
Crinetics Pharmaceuticals, Inc. is led by R. Scott Struthers (age 63), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 00:57 UTC.
| Founder, President, CEO & Director | R. Scott Struthers (age 63) |
|---|---|
| Co-Founder & Chief Scientific Officer | Stephen F. Betz (age 59) |
| Chief Financial Officer | Tobin C. Schilke (age 50) |
| Senior Director of Investor Relations | Gayathri Diwakar |
Major Backers & Investors (CRNX)
Notable institutional backers of Crinetics Pharmaceuticals, Inc. include FMR, LLC, Farallon Capital Management LLC, Wellington Management, according to Nexqual as of June 10, 2026 at 00:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.95% |
| Farallon Capital Management LLC | 7.91% |
| Wellington Management | 7.74% |
| Driehaus Capital Management, LLC | 6.07% |
| Price (T.Rowe) Associates Inc | 5.08% |
| Janus Henderson Group PLC | 4.29% |
| Fidelity | 4.09% |
| EcoR1 Capital, LLC | 4.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.03% |
| BlackRock | 10.22% |
Source: Nexqual, June 10, 2026 at 00:57 UTC.
From Crinetics Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our discovery team has significant expertise in understanding and creating product candidates to influence the dynamic behavior of GPCRs and has developed a number of proprietary methods, techniques and tools that we 5 Table of Contents believe will enable us to efficiently and reliably evaluate newly synthesized molecules.
- We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology, which strengthen and maintain our proprietary position in the field of endocrinology.
- We believe our approach to developing novel small molecule product candidates that uniquely engage peptide hormone GPCRs will enable us to generate orally bioavailable, and potentially more selective, effective and better tolerated therapeutics for patients.
- CRN09682 (non-peptide drug conjugate for SST2 positive solid tumors) We have developed a first-in-class, non-peptide, non-radioactive NDC linking an SST2 agonist with the cytotoxic drug MMAE, via a spacer and a cleavable linker for the treatment of NETs and potentially for use in other solid tumors that express SST2, or SST2+ tumors.
Partnerships
- Paltusotine is also in development for acromegaly in Japan through our licensing agreement with SKK.
- This single-center, in-patient study is in collaboration with the NIDDK of the NIH.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| REPL | Replimune Group, Inc. | USD 9.24 | ▼ 2.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:57 UTC. This page is informational and not investment advice.